These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 29729982)

  • 21. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
    Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
    Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characteristics and outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children.
    Ueda C; Horinouchi T; Inoki Y; Ichikawa Y; Tanaka Y; Kitakado H; Kondo A; Sakakibara N; Nagano C; Yamamura T; Fujimura J; Kamiyoshi N; Ishimori S; Ninchoji T; Kaito H; Shima Y; Iijima K; Nozu K; Yoshikawa N
    Pediatr Nephrol; 2024 Sep; 39(9):2679-2689. PubMed ID: 38662234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
    Hawfield A; Iskandar SS; Smith RJ
    Am J Kidney Dis; 2013 May; 61(5):828-31. PubMed ID: 23391537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis.
    Xiao X; Pickering MC; Smith RJ
    Semin Thromb Hemost; 2014 Jun; 40(4):465-71. PubMed ID: 24799308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
    Le Quintrec M; Lapeyraque AL; Lionet A; Sellier-Leclerc AL; Delmas Y; Baudouin V; Daugas E; Decramer S; Tricot L; Cailliez M; Dubot P; Servais A; Mourey-Epron C; Pourcine F; Loirat C; Frémeaux-Bacchi V; Fakhouri F
    Am J Kidney Dis; 2018 Jul; 72(1):84-92. PubMed ID: 29429752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C3 Glomerulopathy: Pathogenesis and Treatment.
    Ahmad SB; Bomback AS
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):104-110. PubMed ID: 32553242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
    Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
    Front Immunol; 2021; 12():715704. PubMed ID: 34456924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
    Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
    Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.
    Sethi S; Fervenza FC; Zhang Y; Zand L; Vrana JA; Nasr SH; Theis JD; Dogan A; Smith RJ
    Kidney Int; 2012 Aug; 82(4):465-73. PubMed ID: 22673887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defining the complement biomarker profile of C3 glomerulopathy.
    Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update to the pathogenesis for monoclonal gammopathy of renal significance.
    Zuo C; Zhu Y; Xu G
    Crit Rev Oncol Hematol; 2020 May; 149():102926. PubMed ID: 32199132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toward a working definition of C3 glomerulopathy by immunofluorescence.
    Hou J; Markowitz GS; Bomback AS; Appel GB; Herlitz LC; Barry Stokes M; D'Agati VD
    Kidney Int; 2014 Feb; 85(2):450-6. PubMed ID: 24067430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Favorable effect of bortezomib in dense deposit disease associated with monoclonal gammopathy: a case report.
    Hirashio S; Satoh A; Arima T; Mandai K; Awaya T; Oshima K; Hara S; Masaki T
    BMC Nephrol; 2018 May; 19(1):108. PubMed ID: 29724182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Monoclonal Gammopathy-associated C3 Glomerulopathy With Daratumumab-based Therapy.
    Coltoff A; Bomback A; Shirazian S; Lentzsch S; Bhutani D
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e674-e677. PubMed ID: 34023209
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
    Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
    Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dense deposit disease in a child with febrile sore throat.
    Conti G; De Vivo D; Vitale A; Fede C; Santoro D
    Saudi J Kidney Dis Transpl; 2017; 28(4):925-928. PubMed ID: 28748900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of a Histologic Scoring Index for C3 Glomerulopathy.
    Caravaca-Fontán F; Trujillo H; Alonso M; Díaz-Encarnación M; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez E; de la Cerda F; Pérez de José A; López I; Fernández L; Pérez Gómez V; Ávila A; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; González F; Shabaka A; Illescas ML; Calvo C; Oviedo V; Da Silva I; Goicoechea de Jorge E; Caravaca F; Praga M;
    Am J Kidney Dis; 2021 May; 77(5):684-695.e1. PubMed ID: 33359150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C3 glomerulopathy: clinicopathologic features and predictors of outcome.
    Medjeral-Thomas NR; O'Shaughnessy MM; O'Regan JA; Traynor C; Flanagan M; Wong L; Teoh CW; Awan A; Waldron M; Cairns T; O'Kelly P; Dorman AM; Pickering MC; Conlon PJ; Cook HT
    Clin J Am Soc Nephrol; 2014 Jan; 9(1):46-53. PubMed ID: 24178974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eculizumab and recurrent C3 glomerulonephritis.
    Gurkan S; Fyfe B; Weiss L; Xiao X; Zhang Y; Smith RJ
    Pediatr Nephrol; 2013 Oct; 28(10):1975-81. PubMed ID: 23689905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure.
    Ali A; Schlanger L; Nasr SH; Sethi S; Gorbatkin SM
    Am J Kidney Dis; 2016 Mar; 67(3):479-82. PubMed ID: 26704376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.